MedCap AB (CHIX:MCAPS) GF Score: 93/100 (As of Jul. 17, 2026) — 18% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:MCAPS MedCap AB CHIX:MCAPS
93 GF Score
Price kr555.00
GF Value kr596.05
Valuation Fairly Valued
View Full Analysis

What is MedCap AB GF Score?

MedCap AB CHIX:MCAPS 93 GF Score is 93 as of Jul. 17, 2026, which is 18% above its 10-year median of 79.00. GuruFocus rates CHIX:MCAPS with a GF Score™ of 93/100 and a GF Value™ of kr596.05 (Fairly Valued).

MedCap AB has the GF Score of 93, which implies that the company might have Highest outperformance potential.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 8/10
2. Profitability Rank : 8/10
3. Growth Rank : 10/10
4. GF Value Rank : 9/10
5. Momentum Rank : 5/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes MedCap AB might have Highest outperformance potential.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

MedCap AB  (CHIX:MCAPs) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

MedCap AB GF Score Related Terms

CHIX:MCAPS vs ABT, SYK, MDT: GF Score Comparison

For the Medical Devices subindustry, MedCap AB's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MedCap AB GF Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, MedCap AB's GF Score distribution charts can be found below:

* The bar in red indicates where MedCap AB's GF Score falls into.


CHIX:MCAPS
93GF Score
MedCap AB CHIX:MCAPS
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 93 mean?
MedCap AB (CHIX:MCAPS) has a GF Score of 93 as of Jul. 17, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on MedCap AB and its competitors. This is 18% above median its historical median of 79.00. Over the past decade, MedCap AB's GF Score has ranged from 49.00 to 96.00.
Is MedCap AB's GF Score too high?
MedCap AB's current GF Score of 93 is 18% above median its 10-year median of 79.00. Over the past 10 years, this metric has ranged from a low of 49.00 to a high of 96.00. Overall, MedCap AB has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does MedCap AB's GF Score compare to ABT and SYK?
MedCap AB's GF Score of 93 can be compared against companies in the Medical Devices & Instruments industry. Historically, MedCap AB's own GF Score has ranged from 49.00 to 96.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Medical Devices & Instruments company?
A good GF Score depends on the Medical Devices & Instruments industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on MedCap AB and its competitors. MedCap AB's current GF Score is 93, which is 18% above median its own 10-year median of 79.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedCap AB stock overvalued right now?
Based on GuruFocus' analysis, MedCap AB (CHIX:MCAPS) is currently considered Fairly Valued. The stock's GF Value™ is kr596.05, compared to a current price of kr555.00 — trading 6.9% below its estimated fair value. The current GF Score is 93, which is 18% above median its 10-year median of 79.00. MedCap AB's overall GF Score™ is 93/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For MedCap AB (CHIX:MCAPS), the current GF Score is 93 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MedCap AB (CHIX:MCAPS) Overvalued in 2026?

Based on GuruFocus' analysis, MedCap AB stock appears to be undervalued. The current stock price of kr555.00 is trading 6.9% below its estimated GF Value™ of kr596.05. GuruFocus considers MedCap AB to be Fairly Valued.

Key valuation signals for CHIX:MCAPS:

  • GF Score: 93 (18% above median its 10-year median of 79.00)
  • GF Value™: kr596.05 vs. price of kr555.00 (6.9% below fair value)
  • GF Score™: 93/100

No single metric tells the full story. See the CHIX:MCAPS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MedCap AB Business Description

Other Exchanges MCAP:Sweden61MA:Germany
Address Sundbybergsvagen 1, Solna, SWE, 171 73
MedCap AB acquires and develops profitable, market-leading niche companies in the Nordic life science industry. It is diversified into two business areas namely Medical technology and Specialist medicines. Medical Technology mainly develops and sells various medical technology products and services. Its Specialist medicines develop and sell medicines within the regulatory classes of registered, extemporaneous and licensed medicines.
93GF Score

Get the complete analysis for CHIX:MCAPS

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr555.00
Price
kr596.05
GF Value